Home » Symbyax » Symbyax Lawsuit

Symbyax Lawsuit

• More on Symbyax
  • Symbyax Lawsuit

Symbyax is a popular medication that contains the active ingredients found in Zyprexa, as well as the SSRI antidepressant Prozac. Research suggests that SSRIs may increase the risk for heart defects and other congenital abnormalities when taken by pregnant women. Families who believe that pre-natal exposure to this drug may have harmed their child could be eligible to file a Symbyax lawsuit against Eli Lilly & Co.

Symbyax Legal Investigation

The nationwide law firm of Bernstein Liebhard LLP is now investigating legal claims on behalf of families whose children were allegedly born with serious birth defects related to the use of Symbyax. If you would like to learn more about filing a case, please contact our office at (888) 994-5118.

Symbyax: What’s the Problem?

Symbyax is approved to treat depressive episodes associated with bipolar disorder, as well as depression in adults who have already tried unsuccessfully to treat the disorder with two other medications. Symbyax is marketed by Eli Lilly & Co., which also markets Zyprexa and Prozac.

In the past, both Prozac and Zyprexa were the focus of product liability litigations, with Eli Lilly accused of concealing the drugs’ serious side effects. In the case of Prozac, media reports indicate that the pharmaceutical giant had quietly paid more than $50 million to settle claims involving its alleged association with suicidality. Read More

By 2007, Eli Lilly agreed to pay $1.2 billion to 28,500 people who said they developed Type 2 diabetes or other diseases related to the use of the antipsychotic drug, Zyprexa .Two years later, the company pleaded guilty to a charge that it illegally marketed Zyprexa for an unapproved use, and agreed to pay $1.42 billion to settle civil suits and end a federal criminal investigation. Read More

SSRI Antidepressants and Birth Defects

A number of SSRI antidepressants, including Paxil and Zoloft, have also been the subject of litigation involving the drugs’ alleged association with birth defects. Studies published over the years indicate that pre-natal exposure to drugs included in this class may increase the likelihood that a baby will be born with a serious congenital abnormality.

• 2006: An analysis of a Danish Health Registry indicated that that newborns exposed to SSRIs in the first trimester were 60% more likely to have a major birth defect.
• 2007: A New England Journal of Medicine study suggested that mothers who took SSRIs one month prior to conception were more likely to have a baby with anencephaly, craniosynostosis and omphalocele.
• 2009: Research that appeared in the British Medical Journal suggested that expectant mothers who used more than one type of antidepressant in the first trimester were three times more likely give birth to a child with a cardiac septal defect.
• 2011: A paper in Obstetrics and Gynecology reported that expectant mothers who took antidepressants during the first three months of pregnancy were twice as to give birth to a baby with isolated ventricular septal defects and four times more likely to have children with right ventricular outflow tract defects.
• 2016: A study of antidepressants that appeared in JAMA: Pediatrics suggested that the use of SSRIs in the second and third trimester of pregnancy raised the risk of autism spectrum disorder by as much as 117%.

Symbyax Lawsuit Reviews

While there have not been any Symbyax lawsuit filings reported so far, the attorneys at Bernstein Liebhard LLP would like to hear from anyone whose child was born with a major birth defect following pre-natal exposure to this medication. To obtain a free, no-obligation legal review of your potential case, please contact our legal team at (888) 994-5118